[size=0.875]ARTICLES[color=var(--theme-font-color,#fff)][size=0.875]|[color=var(--theme-font-color,#fff)][size=0.875]VOLUME 2, ISSUE 10[color=var(--theme-font-color,#fff)][size=0.875][color=var(--theme-font-color,#fff)][size=0.875], [color=var(--theme-font-color,#fff)][size=0.875]P716-726, [color=var(--theme-font-color,#fff)][size=0.875]OCTOBER 2017[color=var(--theme-font-color,#fff)][color=var(--theme-font-color,#fff)]Download Full Issue
- [color=var(--theme-font-color,#fff)][size=0.875][size=1.6]Purchase
- [color=var(--theme-font-color,#fff)][size=0.875][size=1.6]Subscribe
[color=var(--theme-font-color,#fff)] [size=0.875][size=1.6]Save
[color=var(--theme-font-color,#fff)] [size=0.875][size=1.6]Share
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[size=1.38][color=var(--theme-font-color,#fff)]†
[color=var(--theme-font-color,#fff)]Dr Pol F Boudes, MD [color=var(--theme-font-color,#fff)][size=0.85] [color=var(--theme-font-color,#fff)]†
[color=var(--theme-font-color,#fff)][color=var(--theme-font-color,#fff)][size=0.85]
[color=var(--theme-font-color,#fff)]Prof Mark G Swain, MD
[color=var(--theme-font-color,#fff)]Prof Christopher L Bowlus, MD
[color=var(--theme-font-color,#fff)]Michael R Galambos, MD
[color=var(--theme-font-color,#fff)]Prof Bruce R Bacon, MD
et al.[color=var(--theme-font-color,#fff)]Show all authors
[color=var(--theme-font-color,#fff)]Show footnotes
Published:August 14, 2017DOI:[color=var(--theme-font-color,#fff)]https://doi.org/10.1016/S2468-1253(17)30246-7
Needed Supplementary stuff of the articles. No need for manuscript texts only supplementary files needed.
Thanks
|
10